FDA will review Eisai and Biogen’s Alzheimer’s treatment Leqembi with decision on full approval expected in early July
Medicare has agreed to provide broader coverage once Leqembi receives full FDA approval.
A longevity expert who studied people who live to 110 on how humanity and AI will master aging
BioAge is developing treatments to extend healthy lifespan by targeting molecular causes of aging. Its CEO Kristen Fortney started by studying the super-old.
Schools want to close the Covid learning gap before federal funds run out — here’s how it’s going
States and school districts have less than two years to use the rest of the federal pandemic recovery money earmarked for learning loss.
Tesla cuts Model S and Model X prices in the U.S. to stoke demand
Tesla has cut prices on its two most expensive models in the U.S., the Model S and Model X, in a renewed bid to stoke demand for its cars.
Big tech was a major target at CPAC, but conservatives building alternatives are facing challenges
Big tech was in the crosshairs once again at one of the biggest annual gatherings of conservative politicians and personalities.
Nestle, Tyson and other food giants bet on air fryer boom to grow sales
U.S. consumers spent nearly $1 billion last year buying air fryers, up 51% from 2019.
Salesforce faces an underappreciated risk: Platform customers jumping ship like Veeva
One analyst thinks Salesforce won’t be able to compete well with Veeva in life sciences after their broad-based agreement that bans competition ends in 2025.
Here are the most overbought and oversold stocks on Wall Street right now
The ‘relative strength index’ is one yardstick investors can use to figure out which stocks in the S&P 500 are undervalued or overvalued.
White House physician says lesion removed during Biden’s physical was cancerous, but no further treatment needed
Biden’s doctor said in a memo Friday that a lesion removed from Biden’s chest and sent for biopsy during his health assessment last month was basal cell carcinoma.
